Clinical trial of bevacizumab combined with TOMIRI chemotherapy in the treatment of patients with advanced colorectal cancer
10.13699/j.cnki.1001-6821.2024.15.004
- VernacularTitle:贝伐珠单抗联合TOMIRI化疗治疗晚期结直肠癌患者的临床研究
- Author:
Ye FENG
1
;
Hai GUO
;
Jun-Bin ZHAO
;
Zhi-Xue LI
;
Hai-Peng LIU
Author Information
1. 陇南市第一人民医院胃肠外科,甘肃陇南 746000
- Keywords:
bevacizumab injection;
raltitrexed injection;
irinotecan injection;
progression-free survival;
safety evaluation
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(15):2170-2173
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of bevacizumab injection combined with raltitrexed injection and irinotecan injection(TOMIRI)in the treatment of patients with advanced colorectal cancer.Methods Patients with advanced colorectal cancer were divided into control group and treatment group according to the cohort method.The control group received 180 mg·m-2 irinotecan with intravenous infusion for 30 to 90 min on the first day+3 mg·m-2 raltitrexed with intravenous infusion for 15 min,once every three weeks.On the basis of control group,the treatment group was given 5 mg·kg-1 bevacizumab with intravenous infusion,once every three weeks.Two groups were treated for 4 cycles with 3 weeks per cycle.The clinical efficacy,lesion diameter,Karnofsky performance status(KPS),and adverse drug reactions were compared between two groups.Additionally,based on follow-up results,the progression-free survival(PFS)within 12 months was compared between the two groups.Results The treatment and control groups enrolled 53 patients.After treatment,the total effective rates of treatment and control groups were 83.02％(44 cases/53 cases)and 54.72％(29 cases/53 cases)with statistically significant difference(P＜0.05).After treatment,the tumor diameters of treatment and control groups were(2.44±0.30)and(3.35±0.38)cm;the KPS scores were(78.01±0.79)and(70.69±0.72)points;the PFS was(11.26±1.43)and(8.01±0.97)months,there were statistically significant differences of above indexes between two groups(all P＜0.05).The adverse drug reactions in the treatment group were anemia,abnormal liver and renal function,nausea and vomiting,and leukopenia,which in the control group were gastrointestinal reaction,nausea and vomiting,abnormal liver and kidney function,blood toxicity,anemia and skin rash.The total incidence of adverse drug reactions in treatment and control groups were 11.32％and 28.30％(P＞0.05).Conclusion Bevacizumab injection combined with TOMIRI can helps to enhance the clinical efficacy of advanced colorectal cancer and improve patients'quality of life,improve patient quality of life,prolong PFS,and without increasing the incidence of adverse drug reactions.
